Taylor Stacy L
Known title: SVP and General CounselCIK: 0001799081
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 26,922 | $121K | 8/22/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,772 | $23K | 3/5/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,609 | $23K | 3/5/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 39,990 | $0 | 3/4/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 13,387 | $115K | 3/7/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 85,697 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,491 | $47K | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,387 | $27K | 3/8/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,569 | $19K | 3/7/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 61,779 | $0 | 3/4/2022 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 10,130 | $66K | 12/22/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,208 | $41K | 12/22/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,338 | $460K | 12/22/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 495 | $3K | 9/7/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 495 | $20K | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.